Related Experiment Videos
[Travelers' diarrhea]
1Service de médecine interne et maladies tropicales, Institut de médecine navale, Toulon.
La Revue Du Praticien
|January 15, 1996
Summary
Diarrhoea affects up to 50% of travellers to tropical regions, often caused by enterotoxigenic Escherichia coli. Early fluoroquinolone treatment is recommended for high-risk adults or severe cases.
Area of Science:
- Microbiology
- Travel Medicine
- Infectious Diseases
Context:
- Travellers' diarrhoea is a common ailment affecting up to 50% of individuals journeying from temperate to tropical or subtropical regions.
- Enterotoxigenic Escherichia coli (ETEC) is the predominant bacterial pathogen, implicated in 40-70% of diagnosed cases.
- Laboratory diagnostics are typically reserved for severe, prolonged, or treatment-resistant presentations.
Purpose:
- To summarize the etiology, incidence, and management strategies for travellers' diarrhoea.
- To highlight the role of enterotoxigenic Escherichia coli as a primary causative agent.
- To outline therapeutic and prophylactic considerations for specific risk groups.
Summary:
- Enterotoxigenic Escherichia coli is the leading bacterial cause of travellers' diarrhoea, a frequent condition among international travellers.
- Preventive measures include careful selection of food and beverages.
- For high-risk adults or those unable to tolerate activity interruption, early fluoroquinolone administration is a viable option, balancing efficacy against potential adverse effects.
Impact:
- Informing travellers and healthcare providers about the risks and prevention of travellers' diarrhoea.
- Guiding clinical decisions regarding the empirical treatment and chemoprophylaxis of travellers' diarrhoea.
- Reducing the incidence and impact of travellers' diarrhoea on global mobility and health.